Literature DB >> 23082930

Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data.

A D Seftel1, J de la Rosette, J Birt, V Porter, V Zarotsky, L Viktrup.   

Abstract

OBJECTIVE: Assess and categorise the available prevalence data on coexistent LUTS and ED in the general population and among individuals consulting a healthcare provider for any reason or when seeking treatment for LUTS and/or ED.
METHODS: Literature search of English-language articles published during the last 15 years.
RESULTS: Of 23 relevant studies identified, 12 used both the International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF) as assessment tools and 11 used alternative approaches. In studies using both IPSS and IIEF, overall prevalence of coexistent LUTS/ED of any severity was not assessable for men in the general population, but rates ranged from 14-37% based on alternative assessments. In the general male population, 13-29% had moderate to severe LUTS and 8-35% had moderate to severe ED. In studies using both IPSS and IIEF, overall prevalence of coexistent LUTS and ED of any severity was 71-80% among men seeking treatment for LUTS, and 74% based on alternative assessments. Among men who sought treatment for either condition, 67-100% had moderate to severe LUTS and 43-59% had moderate to severe ED. Coexistence of LUTS and ED increased with age, ranging from 59-86% among men aged 40s to 60s in primary care to 79-100% in treatment-seeking men with LUTS aged 50s to 70s. Impact on QoL varied, but health-related QoL was generally worse in treatment-seeking men compared with men in the general population.
CONCLUSIONS: Although less than one-third of middle-aged and older men in the general population have coexisting LUTS and ED, most men seeking treatment for either LUTS or ED have both conditions. Symptom severity and impact on QoL in each condition increase when LUTS and ED coexist.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23082930     DOI: 10.1111/ijcp.12044

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  26 in total

1.  The prevalence of erectile dysfunction among subjects with late-onset hypogonadism: a population-based study in China.

Authors:  Wen-Hao Tang; Xin-Jie Zhuang; Ru-Ming Shu; Di Guan; Yu-Dang Ji; Bao-Long Zhang; Can-Gang Wang; Li-Hua Zhuang; Zhuo Yang; Kai Hong; Lu-Lin Ma; Hui Jiang; Shan-Jie Zhou; Yi-Qun Gu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.

Authors:  John P Mulhall; Gerald B Brock; Sidney Glina; Simin Baygani; Craig F Donatucci; Mario Maggi
Journal:  J Sex Med       Date:  2016-03-24       Impact factor: 3.802

3.  Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study.

Authors:  I A Korneyev; T A Alexeeva; S H Al-Shukri; A N Bernikov; A A Erkovich; A A Kamalov; M I Kogan; V N Pavlov; V N Zhuravlev; D Y Pushkar
Journal:  Int J Impot Res       Date:  2016-02-11       Impact factor: 2.896

4.  Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction.

Authors:  Sidney Glina; Felipe Placco Araujo Glina
Journal:  Ther Adv Urol       Date:  2013-08

5.  Canadian Urological Association guideline: Erectile dysfunction.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-10       Impact factor: 1.862

6.  Long-term sexual outcomes after holmium laser enucleation of the prostate: which patients could benefit the most?

Authors:  P Capogrosso; E Ventimiglia; M Ferrari; A Serino; L Boeri; U Capitanio; A Briganti; R Damiano; F Montorsi; A Salonia
Journal:  Int J Impot Res       Date:  2016-07-28       Impact factor: 2.896

Review 7.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

8.  Predictors of self-reported benign prostatic hyperplasia in European men: analysis of the European National Health and Wellness Survey.

Authors:  Shonda A Foster; Emily F Shortridge; Marco DiBonaventura; Lars Viktrup
Journal:  World J Urol       Date:  2014-08-07       Impact factor: 4.226

9.  Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.

Authors:  Ran Pang; Xin-Yao Zhou; Xiangling Wang; Bin Wang; Xue-Lai Yin; Hai Bo; Jae Hung Jung
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10

Review 10.  Phosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive review.

Authors:  Albert Haddad; Michel Jabbour; Muhammad Bulbul
Journal:  Arab J Urol       Date:  2015-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.